ACXP — Acurx Pharmaceuticals Share Price
Momentum
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | |||
EPS Growth (f) | |||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | |||
Price to Tang. Book | |||
Price to Free Cashflow | |||
Price to Sales | |||
EV to EBITDA |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | |||
Return on Equity | |||
Operating Margin |
Financial Summary
Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Acurx Pharmaceuticals, Inc., formerly Acurx Pharmaceuticals, LLC, clinical stage biopharmaceutical company. The Company is engaged in developing a class of antibiotics for infections caused by bacteria listed as pathogens by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention, and the United States Food and Drug Administration (FDA). The Company develops antibiotic candidates that block the deoxyribonucleic acid (DNA) polymerase IIIC enzyme (Pol IIIC). Pol IIIC is the primary catalyst for DNA replication of Gram-positive bacterial cells. Its research and development pipeline include clinical stage and early stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile, Enterococcus, including vancomycin-resistant strains (VRE), Staphylococcus, including methicillin-resistant strains (MRSA), and Streptococcus, including antibiotic-resistant strains.
Directors
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- January 1st, 1970
- Public Since
- January 1st, 1970
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 9,541,159
- Address
- 259 Liberty Avenue, STATEN ISLAND, 10305
- Web
- https://www.acurxpharma.com/
- Phone
- +1 9175331469
- Auditors
- CohnReznick LLP
Latest News for ACXP
Similar to ACXP
ABEONA THERAPEUTICS ORD
NASDAQ Capital Market
ACASTI PHARMA CL A ORD
NASDAQ Capital Market
ACHIEVE LIFE SCIENCES ORD
NASDAQ Capital Market
ADDEX THERAPEUTICS ADR
NASDAQ Capital Market
ADVAXIS ORD
NASDAQ Capital Market
FAQ
As of Today at 19:56 UTC, shares in Acurx Pharmaceuticals are trading at $3.77. This share price information is delayed by 15 minutes.
Shares in Acurx Pharmaceuticals last closed at $3.77 and the price had moved by over the past 365 days. In terms of relative price strength the Acurx Pharmaceuticals share price has matched the S&P500 Index by over the past year.
There is no consensus recommendation for this security.
Acurx Pharmaceuticals does not currently pay a dividend.
Acurx Pharmaceuticals does not currently pay a dividend.
Acurx Pharmaceuticals does not currently pay a dividend.
To buy shares in Acurx Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.77, shares in Acurx Pharmaceuticals had a market capitalisation of $35.97m.
Here are the trading details for Acurx Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ACXP
Based on an overall assessment of its quality, value and momentum Acurx Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acurx Pharmaceuticals. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $3.77, shares in Acurx Pharmaceuticals were trading -31.88% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Acurx Pharmaceuticals.
We do not have data on Acurx Pharmaceuticals' directors
We do not have data on Acurx Pharmaceuticals' shareholders